Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review
- Warfarin doesn't prevent death. // Neurology Alert;Jul2012 Pharmacology Watch, p1
The article discusses a study that indicated that warfarin is no more effective than aspirin in preventing mortality in patients with heart failure who are not in atrial fibrillation (AF).
- Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. Homma, Shunichi; Thompson, John L.P.; Pullicino, Patrick M.; Levin, Bruce; Freudenberger, Ronald S.; Teerlink, John R.; Ammon, Susan E.; Graham, Susan; Sacco, Ralph L.; Mann, Douglas L.; Mohr, J.P.; Massie, Barry M.; Labovitz, Arthur J.; Anker, Stefan D.; Lok, Dirk J.; Ponikowski, Piotr; Estol, Conrado J.; Lip, Gregory Y.H.; Di Tullio, Marco R.; Sanford, Alexandra R. // New England Journal of Medicine;5/17/2012, Vol. 366 Issue 20, p1859
Background: It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. Methods: We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day)...
- Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Ferreira, Jorge; Ezekowitz, Michael D.; Connolly, Stuart J.; Brueckmann, Martina; Fraessdorf, Mandy; Reilly, Paul A.; Yusuf, Salim; Wallentin, Lars // European Journal of Heart Failure;Sep2013, Vol. 15 Issue 9, p1053
Aims We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial. Methods and results RE-LY compared two fixed and blinded doses of dabigatran (110 and 150 mg twice daily) with open-label warfarin in 18...
- INTERNAL MEDICINE. Naunton, Mark // Journal of Pharmacy Practice & Research;Mar2010, Vol. 40 Issue 1, p70
The article presents abstracts on internal medicine topics including whether hormone replacement therapy should be abruptly discontinued or gradually tapered, the use of intravenous iron in heart failure and the gastrointestinal bleeding risk associated with antihyperlipidaemic drug use in...
- Warfarin doesn't prevent death. Elliott, William T. // Primary Care Reports;Jul2012 Pharamacology watch, p1
The article discusses a new study, according to which warfarin cannot be recommended for patients with heart failure who are not in atrial fibrillation (AF), as it does not differ in outcome with aspirin and is associated with a higher rate of hemorrhage.
- Influence of heart failure on plasma levels of von Willebrand factor in high risk hypertensive patients. Vintila, A.-M.; Muraru, M.; Anton, M.; Oprisescu, I.; Avram, S.; Bruckner, I. // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 1, p140
An abstract of the article "Influence of heart failure on plasma levels of von Willebrand factor in high risk hypertensive patients," by M. Muraru and colleagues is presented.
- 141 Treatment of hypertensive patients and moderate heart failure with selective adrenoblocker Nebivolol. Nikoghosyan, K.; Gurgenyan, S.; Vatinian, S. // European Journal of Heart Failure. Supplements;
An abstract of the study "Treatment of Hypertensive Patients and Moderate Heart Failure With Selective Adrenoblocker Nebivolol," by S. Vatinian and colleagues is presented.
- Warfarin doesn't prevent death. Elliott, William T. // Neurology Alert;7/1/2012, p1
The article discusses research which suggests that warfarin is no more effective than aspirin in preventing mortality in heart failure patients who are not in atrial fibrillation.
- Antibiotics no benefit in diverticulitis. // Pulse;2/15/2012, Vol. 72 Issue 6, p11
The article reports on the results of the randomised controlled trial, performed by U.S. researchers the difference in the occurrence of death, intracranial haemorrhage, or ischaemic stroke between warfarin and aspirin in patients with heart failure.